ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: CML-LSCs are recognized as being responsible for resistances and relapses that occur despite the advent of BCR-ABL-targeting therapies with Tyrosine Kinase Inhibitors (TKIs).